Sanofi India Limited has informed the Exchange about Retirement of Ms. Renee Amonkar (DIN: 10335917) as the Whole-time Director and Site Director - Goa
SANOFI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.7 pts less than Nifty Microcap 250 and 3.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sanofi India reported Q1 FY26 revenue from operations of ₹4,063 million, down about 12% from ₹4,635 million in Q1 FY25, while profit after tax from continuing operations rose slightly to ₹695 million from ₹682 million. The board approved unaudited results for the quarter and half-year ended 30 June 2025. Ms. Renee Amonkar, Whole-time Director and Site Director – Goa, will retire effective 11 August 2025 and will also cease to be a Key Managerial Personnel. Mr. Mahadev Gawade (ex-Sandoz India, 20+ years in pharma manufacturing and logistics) has been appointed as her replacement for a three-year term. Additionally, the company disclosed a subsequent promotion and distribution agreement with Emcure Pharmaceuticals for its Oral Anti-diabetic (OAD) portfolio.
The director transition looks orderly with a like-for-like internal-style replacement, so governance continuity should not be a concern for shareholders. The sharp revenue drop YoY is a watch-point, though margins held up reasonably well. The Emcure distribution deal could help Sanofi India extend reach for its diabetes brands without building its own field force.